Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. DELL
3. ROIV
4. ANET
5. NKE
6. PANW
7. CL
8. SNDK
9. TAP
10. EAT

Go back to Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
(NASDAQ: PPCB) Delayed: 1.01 -0.01 (0.98%)
Previous Close $1.02    52 Week High $ 
Open $1.05    52 Week Low $ 
Day High $1.05    P/E N/A 
Day Low $0.97    EPS $ 
Volume 194,403       

(NASDAQ: PPCB) Delayed: 1.01 -0.01 (0.98%)
Previous Close $1.02    52 Week High $ 
Open $1.05    52 Week Low $ 
Day High $1.05    P/E N/A 
Day Low $0.97    EPS $ 
Volume 194,403